Volume : 2, Issue : 12, DEC 2016

HYPERLIPIDEMIA AND ATHEROGENIC INDEX IN ASSESSING THE RISK FOR CARDIOVASCULAR DISEASE IN THE POPULATION OF ELBASAN DISTRICT

MIMOZA KUÇI, TEFTA REXHA

Abstract

Hyperlipidemia is a major risk factor for atherosclerosis and cardiovascular disease. It is usually asymptomatic until serum lipid levels are severely elevated, and cardiovascular morbidity and mortality are increased. A sample population consisting of 160 persons from Elbasan district, was taken into examination. They were examined about blood analyses for the level of: triglycerides, total cholesterol, HDL-cholesterol and LDL-cholesterol. The determination of Hi squares is used to see the potential between variables. We studied the significance of two important lipid ratios Castelli’s risk index TC/HDL and LDL/HDL in predicting the risk for CVD. A case control study was conducted with 80 patients and 80 healthy volunteers. Lipid profile was measured on automated analyzer. LDL-ch and Castelli’s risk indexes were calculated for both case and control group. These ratios were significantly different (p<0.05) between groups. These are the calculated fraction that can be used in the clinical setting for assessing the risk for CVD beyond the doing of lipid profile. The objective of the present study is to assess the significance of hyperlipidemia and the lipid ratios like Castelli’s Index in identification, of at risk individuals for cardiovascular diseases beyond the routinely done lipid profile.

Keywords

Cardiovascular Diseases (CVD), HDL-Cholesterol, LDL-Cholesterol, Castelli’ Risk Index.

Article : Download PDF

Cite This Article

Article No : 20

Number of Downloads : 881

References

[1] Allain, C. C., Poon, L. S. & Chan, C. S. G. (1974). Enzymatic determination of total serum cholesterol. Clin. Chem., 20, 470-475. [2] Assmann, G., Schriewer, H., Schmitz, G. & Hagele, E.O. (1983). Quantification of HDL-C by precipitation with phosphotungstic acid and MgCl2. Clin. Chem., 29(12), 2026- 2030. [3] Buccolo, G. & David, H. (1973). Quantitative determination of serum triglyceride by the use of enzymes. Clin. Chem.,19: 476-482. [4] Libby, P., Aikawa, M. & Schonbeck, U. (2000). Cholesterol and atherosclerosis. Biochim Biophys Acta 1529: 299–309. [5] Daphna Weissglas-Volkov and Pajukanta P., Genetic causes of high and low serum HDL cholesterol. The Journal of Lipid Research, 51:2032-2057 (2010) [6] Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H., A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med, 325:373–81 (1991).
[7] Ridker P.M., Stampfer M.J., Rifai N., Novel risk factors for systemic atherosclerosis: a comparison of Creactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA, 285:2481–2485 (2001). [8] Brehm A., Pfeiler G., Pacini G., Vierhapper H., and Roden M., Relationship between Serum Lipoprotein Ratios and Insulin Resistance in Obesity. Clin. Chem., 50: 2316–2322 (2004). [9] Richmond N., Clin Chem, 19:1350-1356 (1973). [10] Jacobs N.J., Van Denmark P.J., Arch Biochem Biophys, 88:250-255 (1960). [11] Lopes-virella M.E., Stone P., Elliss S., Cholesterol determination in high density Lipoprotein separated by three different methods. Clin Chem, 23:882 (1977). [12] Freidwald W.T., Levy R.I., Fredrickson D.S., Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 18:499-502 (1972). [13] National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP)Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106:3143–3421 (2002). [14] Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 364 (9438):937-952, (2004). [15] John D. Brunzell, Hypertriglyceridemia. N Engl J Med, 357:1009-1017 (2007) [16] Genest J., Frohlich J., Fodor G,. McPherson R., The Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: 2003 update. CMAJ, 169:921–924 (2003). [17] Von Eckardstein A., Nofer J.R., Assmann G., High density lipoproteins and arteriosclerosis: Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol, 21:13–27 (2001). [18] Castelli W.P., Abbott R.D., McNamara P.M., Summary estimates of cholesterol used to predict coronary heart disease. Circulation, 67(4): 730-734 (1983).
[19] Dyslipidemia of Central Obesity and Insulin Resistance. Improving Prognosis in Type 1 Diabetes. Proceedings from an Official Satellite Symposium of the
Research Paper E-ISSN NO : 2455-295X | VOLUME : 2 | ISSUE : 12 | DEC 2016
I N T E R N A T I O N A L E D U C A T I O N A L S C I E N T I F I C R E S E A R C H J O U R N A L
105
16th International Diabetes Federation Congress. Diabetes Care, (22) S3.